Xilio Therapeutics (XLO) Net Cash Flow Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 53.46% |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | -62.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.09% |
| Dec 31, 2025 | 666.57% |
| Sep 30, 2025 | -29.93% |
| Jun 30, 2025 | -18.78% |
| Mar 31, 2025 | 453.88% |
| Dec 31, 2024 | 60.42% |
| Sep 30, 2024 | 12.31% |
| Jun 30, 2024 | 323.67% |
| Mar 31, 2024 | 64.78% |
| Dec 31, 2023 | 19.69% |
| Sep 30, 2023 | 22.99% |
| Jun 30, 2023 | -1.90% |
| Mar 31, 2023 | -28.51% |
| Dec 31, 2022 | -119.08% |
| Sep 30, 2022 | 1.31% |
| Jun 30, 2022 | 16.13% |
| Mar 31, 2022 | -117.29% |
| Dec 31, 2021 | 874.64% |